All In Biotech

Drug Trial Radar · NCT03921528

An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients With Later-Onset Spinal Muscular Atrophy (TOPAZ)

Last checked: Nov 20, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Apr 22, 2019

Primary completion

Jan 19, 2021

Study completion Feb 28, 2024

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Apr 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TOPAZ study will assess the safety and efficacy of SRK-015 in later-onset Spinal Muscular Atrophy (SMA Type 2 and Type 3) in pediatric and adult patients.

Conditions

  • Spinal Muscular Atrophy
  • Spinal Muscular Atrophy Type 3
  • Spinal Muscular Atrophy Type 2
  • SMA
  • Neuromuscular Diseases
  • Muscular Atrophy
  • Atrophy
  • Muscular Atrophy, Spinal
  • Neuromuscular Manifestations

Interventions

  • SRK-015Biological

    SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12]Time frame: Baseline up to 12 months
  2. Cohort 2 and Cohort 3: Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score at Day 364 (Visit 15) [Month 12]Time frame: Baseline up to 12 months

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Stanford University

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • The Johns Hopkins University

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan

  • Columbia University

    New York, New York

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • Childrens Medical Center Dallas

    Dallas, Texas

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Università Cattolica Sacro Cuore

    Roma, Italy

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.